The unpredictable nature of postpartum hemorrhage
and its potential for severe morbidity and mortality make identifying its risk factors a priority.
There are various factors affecting the postpartum hemorrhage
treatment devices market such as rising prevalence of postpartum hemorrhage
cases; increasing awareness of peoples regarding postpartum hemorrhage
; increasing postpartum hemorrhage
risk factors; technological advancement in medical device field; and, so on.
Access to skilled health care providers and appropriate uterotonic medications such as oxytocin could eliminate many deaths from postpartum hemorrhage
. As discussed earlier, however, the answer is not as simple as educating women and their families about the need for facility births.
Uterine artery ligation in the control of intractable postpartum hemorrhage
. Am J Obstet Gynecol 1966;94:920-4.
However, lack of product awareness in the emerging economies and low acceptance of unconventional preventive devices would hamper the growth of the postpartum hemorrhage
treatment devices market during the forecast period.
is the leading cause of maternal death globally and contributes to an estimated third of all maternal deaths in Africa (6).
While UAE is a highly effective measure to control postpartum hemorrhage
, it is not available at all obstetric hospitals.
However, in the setting of acute postpartum hemorrhage
, MDCT can be the modality of choice to investigate the source of bleeding.
As postpartum haemorrhage is a lethal complication of delivery and is associated with high maternal mortality and morbidity, so the purpose of this study was to compare the success rate of intrauterine balloon tamponade and B Lynch suture for management of severe postpartum hemorrhage
in local population.
(PPH, excessive bleeding after delivering a baby) is a leading cause of maternal complications during birth, leading to emergency intervention including hysterectomy, expensive blood transfusions, and, in some cases, maternal death.
(5.) WHO recommendations for the prevention and treatment of postpartum hemorrhage
. Geneva: World Health Organization; 2012.
22, 2018 (HealthDay News) -- Prophylactic administration of tranexamic acid does not reduce postpartum hemorrhage
among women with vaginal delivery receiving prophylactic oxytocin, according to a study published in the Aug.